We have refined the technique for isolating and propagating cultures of primary ovarian carcinosarcoma cells (OSCs) derived from ascites, which allowed the cells to obtain the biphasic features of carcinosarcoma in cell culture conditions (presence of both carcinoma and mesenchymal morphologic types). This protocol involves a simple yet rapid method for the growth and propagation of ascites OSC in a basal culture medium. Autologous ascitic fluid was used as source of growth factors, and minimal manipulation was involved to establish the culture. The methodology allowed for the direct application of multiple molecular, cellular, and functional analyses within a few weeks of initial cell isolation, with the further potential of retrospective analyses of archived cells and tissues.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369227PMC

Publication Analysis

Top Keywords

ovarian carcinosarcoma
8
ascitic fluid
8
presence mesenchymal
4
mesenchymal carcinomatous
4
carcinomatous features
4
features in-vitro
4
in-vitro model
4
model ovarian
4
carcinosarcoma derived
4
derived patients'
4

Similar Publications

Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes.

Front Oncol

December 2024

Department of Gynaecologic Oncology, Center for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam University Medical Centres, Amsterdam, Netherlands.

View Article and Find Full Text PDF

Ovarian carcinosarcoma (OCS) is a rare and aggressive tumor, and the development of its sarcomatous component is believed to be due to epithelial-mesenchymal transition (EMT). The SWIch/sucrose nonfermentable chromatin remodeling factor (CRF) is closely related to EMT; however, the relationship between CRF and EMT in OCS remains unclear. In this study, we analyzed the protein expression of CRFs, including ARID1A and SMARCA4, and their downstream mRNA expression in 28 OCS cases, two fallopian tube CS cases, and one peritoneal CS case.

View Article and Find Full Text PDF

The aim of the present study was to evaluate the occurrence of synchronous or metachronous hematologic and gynecologic malignancies. The medical database of the pathology department at a tertiary center was searched from 2016 to 2024 for cases involving both hematologic and gynecologic tumors. A literature search using Google Scholar and PubMed was also conducted between May and June 2024.

View Article and Find Full Text PDF
Article Synopsis
  • HER2 overexpression is a significant target for treating gynecological cancers, and Trastuzumab-Deruxtecan (T-DXd) has shown notable effectiveness against these cancers, particularly in ovarian, endometrial, and cervical malignancies.
  • A study was conducted at the Alexandra Hospital in Athens involving 10 patients with HER2-positive gynecological cancers who were treated with T-DXd, administered intravenously every 3 weeks.
  • Results indicated a median progression-free survival of 5.4 months, with 5 patients achieving a partial response, highlighting T-DXd's potential as a treatment option even for patients with prior therapies.
View Article and Find Full Text PDF
Article Synopsis
  • Carcinosarcoma is a rare and aggressive malignant tumor of the uterus and ovaries, often confused with high-grade endometrial carcinoma due to similar symptoms.
  • A study conducted between August 2021 and July 2024 analyzed six cases, confirming their diagnosis through a panel of immunohistochemical markers, with mean patient age being 51.5 years.
  • Histologically, the tumors displayed a biphasic composition of carcinomatous and sarcomatous elements, with notable positivity for markers like cytokeratin and vimentin, highlighting their complex nature and aggressive behavior in elderly females.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!